Search Results
Jun 12, 2026, 12:02 ET University of Arizona Announces Landmark $14 Million PCORI-Funded Clinical Trial Comparing Three Leading Treatments for Obstructive Sleep Apnea
obstructive sleep apnea (OSA) treatments to date. Funded by a five-year, nearly $14 million award from the Patient-Centered Outcomes Research Institute (PCORI), the study will enroll 2,400 patients across four major academic medical centers to help patients and physicians make better-informed OSA treatment decisions.
More news about: Daybreak
Jun 10, 2026, 12:02 ET Daybreak and Veterans Healthcare Supply Solutions Partner to Bring Oral Appliance Therapy for Obstructive Sleep Apnea to Veterans Nationwide
(OAT) for obstructive sleep apnea (OSA) available to veterans through VA Healthcare facilities nationwide. The agreement marks a significant expansion in access to a clinically proven, non-CPAP treatment option for the millions of veterans living with untreated OSA.
More news about: Daybreak
Jun 10, 2026, 09:30 ET Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
moderate-to-severe OSA is really like – the stuff you don't usually see on TV. I'm also going to be out in communities, meeting people face-to-face, because sometimes the best way to get someone to recognize the symptoms of OSA is to show up and have a real conversation.What is OSA?OSA is a sleep-related
More news about: Eli Lilly and Company
Jun 10, 2026, 08:00 ET Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA, including the
More news about: Apnimed, Inc.
Jun 10, 2026, 08:00 ET Wesper to Unveil First Multi-Tier Sleep Diagnostic Ecosystem for Personalized Sleep Care at SLEEP 2026
patient——Company to present three posters reinforcing Wesper's autoscoring precision, AI-driven central apnea detection, and OSA phenotyping in obese patients that standard AHI misses—NEW YORK, June 10,
More news about: Wesper
Jun 08, 2026, 14:30 ET Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist
More news about: Eli Lilly and Company
Jun 08, 2026, 10:00 ET Bloomberg Media solmii kumppanuuden Cisionin kanssa tuodakseen journalisminsa viestinnän työnkulkuihin
tavoittavuutta samalla, kun luomme yhteisille tilaajillemme saumattoman ja integroidun kokemuksen." "Viestintätiimeille luotettava journalismi on tärkeä osa niiden organisaatioille merkittävien uutisten, aiheiden ja markkinamuutosten ymmärtämistä. Tämä kumppanuus tarjoaa asiakkaille helpomman pääsyn Bloomberg
More news about: Cision Ltd.
Jun 08, 2026, 08:00 ET Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA, including the
More news about: Apnimed, Inc.
Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
semaglutide injection 2.4 mg on risk of MACE in participants with reported OSA as well as incidence of OSA. A questionnaire identified OSA at baseline and incident OSA was captured via adverse event reporting in those without OSA at baseline. At baseline, 2,550 participants (14.5%) reported having OSA.1Semaglutide
More news about: NOVO NORDISK INC.
Jun 04, 2026, 04:22 ET Uusi Apica-tutkimus: Agenttinen tekoäly on valmis laukaisemaan 9,5-kertaisen telemetriatietojen räjähdysmäisen kasvun, joka jättää suurimman osan yrityksistä haavoittuvaisiksi
havainnointiratkaisujensa muutoksia kuuden kuukauden kuluessa. 70 % suunnittelee arvioivansa telemetriakanavointien ratkaisuja samoissa puitteissa. Suurin osa tämän raportin lukijoista on jo aktiivisen arviointijakson puitteissa tai aloittamassa sellaisen.Tutkimusraportti on nyt saatavilla. Täydellisten
More news about: Apica
Jun 04, 2026, 03:00 ET UGREEN liittyy vuoden 2026 Terra Wortmann Openin viralliseksi kumppaniksi teemalla "Virtaa peliisi"
tulla paikalle ja joissa kannattaa olla täysin mukana. Tämä kasvava maailmanlaajuinen jalansija osoittaa, kuinka brändin ratkaisut ovat yhä useammin osa tosielämän kokemuksia, joissa suorituskyvyllä on merkitystä, ja varmistavat, että virtaa ja yhteyksiä riittää joka hetkeen ilman katkoksia.Tietoa
More news about: UGREEN Limited
May 28, 2026, 13:00 ET Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
May 28, 2026, 06:45 ET Foundayo and Zepbound now covered for millions of Americans
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
May 20, 2026, 10:45 ET Northeastern University Demonstrates First Open-Source Prototype of a Massive MIMO AI-RAN System
www.amplitechgroup.comAbout OpenAirInterface Software Alliance (OSA)The OpenAirInterface Software Alliance is a non-profit organization developing open-source software implementations of 3GPP standards for
More news about: Institute for Intelligent Networked Systems
May 18, 2026, 07:00 ET Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed has submitted
More news about: Apnimed, Inc.
May 16, 2026, 13:38 ET TTW Ranks the Top 50 Wellness Destinations in the World for 2026
rejuvenation. From the volcanic hot springs of Arenal and the serene beaches of Guanacaste to the cloud forests of Monteverde and the tropical jungles of the Osa Peninsula, the country offers landscapes that naturally foster relaxation, emotional balance, and spiritual renewal. Costa Rica's wellness experiences
More news about: Travel And Tour World
May 13, 2026, 10:00 ET PR nousee toimittajien tärkeimmäksi tietolähteeksi kiireisissä toimituksissa
-raporttinsa, joka paljastaa muutoksen mediaympäristön toiminnassa: PR ei enää pelkästään esittele juttuehdotuksia, vaan siitä on tulossa keskeinen osa modernin uutistoimituksen toimintaa.
More news about: Cision Ltd.
May 12, 2026, 18:01 ET Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
weight-related medical problems, to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
May 12, 2026, 10:00 ET Dooap Inc. lanseeraa Dooap Studion: Agenttipohjainen ostoreskontran automatisointi suoraan taloushallinnon tiimien käyttöön
Lainaus Anna T:ltä, CPO"Kehitimme Studion, koska sääntöihin perustuvan automaation rajat ovat todelliset ja suurin osa ostoreskontran tekoälystä on vain hyvin pitkä komento, jossa toivotaan parasta. Studio tuo tekoälyyn rakennetta ja hallittavuutta: nyt ostoreskontra
More news about: Dooap Inc
May 12, 2026, 08:06 ET The Dyrt Announces The 2026 Glampy Awards Presented by Ramble
Osa Trail — New York: A single site on a hilltop in the heart of the Catskills
More news about: The Dyrt
May 12, 2026, 02:00 ET Bindex tuo osteoporoosin varhaisen tunnistamisen Boots-apteekkeihin Isossa-Britanniassa
henkilökohtaisesta osteoporoosiriskistä entistä varhaisemmassa vaiheessa ja kannustaa ennakoiviin toimiin ennen murtumien syntymistä. Samalla se on osa terveydenhuollon laajempaa muutosta, jossa palveluja tuodaan sairaaloista lähemmäs ihmisten arkea.
More news about: Bone Index Finland Ltd.
May 11, 2026, 08:00 ET Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA.Learn more
More news about: Apnimed, Inc.